Approaches to prevention of flu at elderly

   Influenza retains a special place among human infectious diseases, due to its ubiquitous distribution, annual outbreaks and epidemics. Complicated forms of influenza are one of the main causes of death in the world. Influenza poses a significant risk to the elderly: patients aged 60 years and older make up the majority of hospitalized influenza patients and are more likely to become severely ill. In addition to the severe manifestation of respiratory symptoms and viral pneumonia in elderly patients with influenza, data are presented on the complications of influenza from the respiratory, central nervous and other systems, and the risk of heart attack and stroke. Approaches to vaccination against influenza, including the elderly, are considered. The use of influenza vaccines reduces the risk of hospitalization due to diseases of the cardiovascular and respiratory systems, reduces overall mortality, and these effects are most pronounced in people of older age groups. Influenza vaccination of older adults reduces severe illness and complications by 60 % and deaths by 80 %. Persons over 60 years of age in the Russian Federation are immunized against influenza as part of the National Immunization Schedule. For the elderly (both healthy and at risk), a single annual vaccination is recommended at least 2-3 weeks before the start of the seasonal rise (in most cases from October to May), and can also be carried out during the influenza season. Russia uses inactivated influenza vaccines. To increase the immunogenicity of vaccines while maintaining their low reactogenicity, it is common to add immunoadjuvants to the vaccine composition, which are part of the domestic vaccines. The Russian influenza vaccine that meets all WHO recommendations on the qualitative and quantitative content of influenza virus antigens is trivalent inactivated split influenza vaccine. The current priority is the use of quadrivalent vaccines, which ensure the development of the most stable immunity. In Russia, such a vaccine, which meets all WHO recommendations, is quadrivalent inactivated split influenza vaccine. The article presents the characteristics of influenza vaccines used in the Russian Federation and data on their effectiveness, including in the elderly.

1. Swets M. C., Russell C. D., Harrison E. M., Docherty A. B., Lone N., Girvan M., Hardwick H. E.; ISARIC4C Investigators, Visser L. G., Openshaw P. J. M., Groeneveld G. H., Semple M. G., Baillie J. K. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses // Lancet. 2022; 399 (10334): 1463-1464. DOI: 10.1016/S0140-6736(22)00383-X. Epub 2022 Mar 25. PMID: 35344735; PMCID: PMC8956294.

2. Lo Re V., Dutcher S. K., Connolly J. G., et al. Association of COVID-19 vs Influenza With Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients // JAMA. 2022; 328 (7): 637-651. DOI: 10.1001/jama.2022.13072.

3. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2021 году: Государственный доклад. – М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2022. – 340 с. [On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2021: State report. M.: Federal'naya sluzhba po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka, 2022. P. 340/]

4. Tan L. Adult vaccination: now is the time to realize an unfulfilled potential // Human Vacc Immunother. 2015; 9: 2158-2166.

5. Bula C. J., Ghiraldi G., Weitlisbach V., et al. Infections and functional impairment in nursing home residents: a reciprocal relationship // J Am Geriatr Soc. 2004; 52: 700-706.

6. Aging of the Immune System. Mechanisms and Therapeutic Targets. Cornelia M. Weyandcorresponding author and Jоrg J. Goronzy // Ann Am Thorac Soc. 2016; 13 (Suppl 5): S422-S428.

7. Грипп у взрослых: диагностика, лечение, способы и методы неспецифической профилактики. Методические рекомендации / Под ред. А. В. Васина, Т. В. Сологуб. – СПб, 2016. – 82 с. [Influenza in adults: diagnosis, treatment, methods of nonspecific prevention. Guidelines. Pod red. Vasina A. V., Sologub T. V. Sankt-Peterburg, 2016. Р. 82.]

8. Смородинцева Е. А. Влияние современных эпидемий гриппа на смертность взрослого населения от соматических болезней / Е. А. Смородинцева, И. Г. Маринич, К. А. Столяров // Вестник Российской военно-медицинской академии. – 2008. – 2 (22). – 367-368. [Smorodintseva Ye. A., Marinich I. G., Stolyarov K. A. nfluence of modern influenza epidemics on adult mortality from somatic diseases // Vestnik Rossiyskoy voyenno-meditsinskoy akademii. 2008. № 2 (22). Pp. 367-368.]

9. Краснова Е. И. Грипп в период пандемии COVID-19, эпидемиологическая характеристика, подходы к вакцинации / Е. И. Краснова [и др.] // Лечащий Врач. – 2021. – 4 (24). – 50-56. DOI: 10.51793/OS.2021.98.48.009. [Krasnova Ye. I., Karpovich G. S., Provorova V. V., Shestakov A. Ye., Kazakova Yu. V. Influenza during the COVID-19 pandemic, epidemiological characteristics, approaches to vaccination // The Lechaschi Vrach Journal 2021; 4 (24): 50-56. DOI: 10.51793/OS.2021.98.48.009. ]

10. Методические рекомендации подготовлены по инициативе Общероссийской общественной организации «Российская ассоциация геронтологов и гериатров». Версия 1. – М., 2020. – 50 с. [Methodological recommendations were prepared on the initiative of the All-Russian Public Organization «Russian Association of Gerontologists and Geriatricians» Version 1. Moskva, 2020. Р. 50.]

11. Udell J. A., et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis // J. Am. Med. Assoc. 2013; 310: 1711-1720. DOI: 10.1001/jama.2013.279206.

12. Yedlapati S. H., et al. Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis // J. Am. Heart Assoc. 2021; 10: e019636. DOI: 10.1161/JAHA.120.019636.

13. Behrouzi B., Udell J. A. Universal flu vaccines: a shot at lifelong cardioprotection? // Nat Rev Cardiol. 2022; 19 (3): 145-146. DOI: 10.1038/s41569-021-00670-w. PMID: 35027698; PMCID: PMC8757624.

14. Fröbert O., et al. Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial // Circulation. 2021; 144: 1476-1484. DOI: 10.1161/CIRCULATIONAHA.121.057042.

15. Vardeny O., et al. Effect of high-dose trivalent vs standard-dose quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk cardiovascular disease: a randomized clinical trial // J. Am. Med. Assoc. 2021; 325: 39-49. DOI: 10.1001/jama.2020.23649.

16. Hollingsworth R., et al. Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: rationale and design of a real-world pragmatic randomized clinical trial // Am. Heart J. 2021; 237: 54-61. DOI: 10.1016/j.ahj.2021.03.007.

17. Loeb M., et al. Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): rationale and design // Am. Heart J. 2019; 212: 36-44. DOI: 10.1016/j.ahj.2019.02.009.

18. Seo Y. B., Suk Choi W., Hyeon Baek J. et al. Effectiveness of the influenza vaccine at preventing hospitalization due to acute exacerbation of cardiopulmonary disease in Korea from 2011 to 2012 // Human Vaccines & Immunotherapeutics. 2014; 10 (2): 423-427.

19. Никоноров И. Отечественный препарат последнего поколения для профилактики гриппа / И. Никоноров [и др.] // Врач. – 2014. – 3. [Nikonorov I., Maksakova V., Fel'dblyum I., Konshina O., Yerofeyeva M. Domestic drug of the latest generation for the prevention of influenza // Vrach. 2014; 3.]

20. Селькова Е. П. Эпидемиологическая значимость вакцинопрофилактики гриппа. Отечественная противогриппозная вакцина последнего поколения / Е. П. Селькова [и др.] // Эпидемиология и инфекционные болезни. – Актуальные вопросы. – 2014. – 4. [Sel'kova Ye. P., Grenkova T. A., Gudova N. V., Oganesyan A. S., Polezhayeva N. A. Epidemiological significance of influenza vaccination. Domestic influenza vaccine of the last generation // Epidemiology and infectious diseases.Aktual'nyye voprosy. 2014; 4.]

21. Erofeeva М. К., Nickonorov I. J., Maksakova V. L., Stukova M. A., Konshina O.S., Okhapkina E. A., Voicehovskaya E. M., Korovkin S. A., Melnikhov S. J., Kiselev O. I. Protective Properties of Inactivated Virosomal Influenza Vaccine // Procedia in Vaccinology. 2014; 8: 24-33. 7th Vaccine & ISV Annual Global Congress.

22. Вакцинация от гриппа – надежный способ пережить эпидемический сезон // Ремедиум. – 2016. – 12. URL: https://cyberleninka.ru/article/n/vaktsinatsiya-ot-grippa-nadezhnyy-sposob-perezhit-epidemicheskiy-sezon (дата обращения: 22. 02. 2021). [Flu vaccination is a reliable way to survive the epidemic season // Remedium. 2016; 12. URL: https://cyberleninka.ru/article/n/vaktsinatsiya-ot-grippa-nadezhnyy-sposob-perezhit-epidemicheskiy-sezon (Accessed: 22. 02. 2021).]

23. Concept Paper on the Revision of the CPMP/BWP Note for Guidance on Harmonization of Requirements for Influenza Vaccines (CPMP/BWP/214/96). London, 31 May, 2001/CPMP/EWP/1045/01.

24. Селькова Е. П. Изучение иммуногенности, эффективности и переносимости отечественной вакцины «Ультрикс®» среди лиц повышенного риска инфицирования и заболеваемости гриппом и острыми респираторными вирусными инфекциями / Е. П. Селькова [и др.] // Эпидемиология и инфекционные болезни. Актуальные вопросы. – 2016. – 1. – 59-66. [Sel'kova Ye. P., Grenkova T. A., Aleshkin V. A., Gudova N. V., Lytkina I. N., Mikhaylova Ye. V., Yashina A. Ya., Fedyakina I. T. Study of the immunogenicity, efficacy and tolerance of the domestic vaccine «Ul'triks®» among persons at increased risk of infection and the incidence of influenza and acute respiratory viral infections // Epidemiologiya i infektsionnyye bolezni. Aktual'nyye voprosy. 2016; 1: 59-66.]

25. Маркова Т. П. Вакцинопрофилактика гриппа. Новая отечественная вакцина Ультрикс® / Т. П. Маркова, Л. Г. Ярилина, М. Н. Ким // Русский медицинский журнал. – 2014. – 25. – 1862. https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Vakcinoprofilaktika_grippa_Novaya_otechestvennaya_vakcina_Ulytriks/#ixzz7asgFdpSK. [Markova T. P., Yarilina L. G., Kim M. N. Influenza vaccination. New domestic vaccine Ultrix® // RMJ. 2014; 25: 1862. https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Vakcinoprofilaktika_grippa_Novaya_otechestvennaya_vakcina_Ulytriks/#ixzz7asgFdpSK.]